Survival of patients after lymphocytotoxic monoclonal antibody therapy for RA.

Survival of patients after lymphocytotoxic monoclonal antibody therapy for RA.

Opis bibliograficzny
Główni autorzy:	Isaacs, J, Greer, S, Symmons, D, Sharma, S, Hale, G, Waldmann, H, Hazleman, B
Format:	Journal article
Wydane:	1998

Podobne zapisy

Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
od: Isaacs, J, i wsp.
Wydane: (2004)

Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
od: Isaacs, J, i wsp.
Wydane: (2005)

Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
od: Isaacs, J, i wsp.
Wydane: (2005)

HUMANIZED MONOCLONAL-ANTIBODY THERAPY IN RHEUMATOID-ARTHRITIS
od: Isaacs, J, i wsp.
Wydane: (1992)

Humanised monoclonal antibody therapy for rheumatoid arthritis.
od: Isaacs, J, i wsp.
Wydane: (1992)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
od: Isaacs, J, i wsp.
Wydane: (1996)

Morbidity not increased in rheumatoid arthritis patient with profound lymphopenia following CD4 monoclonal antibody therapy: comment on the article by Isaacs et al - Reply
od: Isaacs, J, i wsp.
Wydane: (2002)

Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia.
od: Isaacs, J, i wsp.
Wydane: (2001)

A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans.
od: Isaacs, J, i wsp.
Wydane: (1996)

Humanized monoclonal antibody treatment in rheumatoid arthritis.
od: Kyle, V, i wsp.
Wydane: (1991)

HUMANIZED MONOCLONAL-ANTIBODY THERAPY FOR SYSTEMIC VASCULITIS
od: Lockwood, C, i wsp.
Wydane: (1993)

Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.
od: Lockwood, C, i wsp.
Wydane: (1993)

HUMANIZED MONOCLONAL-ANTIBODY (MAB) THERAPY FOR WEGENERS GRANULOMATOSIS (WG)
od: Lockwood, C, i wsp.
Wydane: (1995)

MONOCLONAL-ANTIBODIES IN SYSTEMIC VASCULITIS - LONG-TERM BENEFIT FROM SHORT-TERM THERAPY
od: Isaacs, J, i wsp.
Wydane: (1993)

Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes.
od: Lorenzi, A, i wsp.
Wydane: (2008)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
od: Watts, R, i wsp.
Wydane: (1992)

The lymphocytotoxic effect of homoprobiotic bifidobacteria and lactobacilli autostrains
od: I. P. Pogorelsky, i wsp.
Wydane: (2014-09-01)

Monoclonal-antibody therapy in systemic vasculitis.
od: Mathieson, P, i wsp.
Wydane: (1990)

Aglycosyl anti-CD3 monoclonal antibody therapy in rheumatoid arthritis - Results of a pilot safety study
od: Lawson, C, i wsp.
Wydane: (2005)

Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential.
od: Isaacs, J, i wsp.
Wydane: (1992)

EFFECTS OF MONOCLONAL-ANTIBODIES OF THE CAMPATH SERIES INVIVO - REQUIREMENTS FOR EFFECTIVE ANTIBODY THERAPY
od: Dyer, M, i wsp.
Wydane: (1988)

BIOLOGICAL EFFECTS OF A HUMAN IGG4 MONOCLONAL-ANTIBODY IN-VIVO
od: Isaacs, J, i wsp.
Wydane: (1995)

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.
od: Isaacs, J, i wsp.
Wydane: (1995)

Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T cells in rheumatoid arthritis.
od: Kyle, V, i wsp.
Wydane: (1989)

Advantages of rat monoclonal antibodies.
od: Clark, M, i wsp.
Wydane: (1983)

Specificity of monoclonal antibody Campath-1.
od: Hale, G, i wsp.
Wydane: (1988)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
od: Hale, G, i wsp.
Wydane: (1994)

Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies.
od: Lockwood, C, i wsp.
Wydane: (1996)

Combination therapy with a TNF antagonist and a CD4 monoclonal antibody in rheumatoid arthritis. A pilot study.
od: Morgan, A, i wsp.
Wydane: (1997)

Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance.
od: Waldmann, H, i wsp.
Wydane: (2001)

Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies.
od: Isaacs, J, i wsp.
Wydane: (1994)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
od: Lim, S, i wsp.
Wydane: (1993)

Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease.
od: Isaacs, J, i wsp.
Wydane: (1997)

Induction of tolerance by monoclonal antibody therapy.
od: Benjamin, R, i wsp.
Wydane: (1986)

Interaction of rat monoclonal antibodies with human killer cells.
od: Clark, M, i wsp.
Wydane: (1985)

Therapeutic potential of monoclonal antibodies to the leucocyte common antigen.
od: Bindon, C, i wsp.
Wydane: (1985)

MONOCLONAL-ANTIBODIES TO HEMATOPOIETIC-CELLS
od: Waldmann, H, i wsp.
Wydane: (1982)

MONOCLONAL-ANTIBODY THERAPY IN SYSTEMIC VASCULITIS
od: Mathieson, P, i wsp.
Wydane: (1990)

Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.
od: Bindon, C, i wsp.
Wydane: (1988)

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H.
od: Newman, D, i wsp.
Wydane: (1995)